Dermapharm Holding SE (DMP.DE)
EUR 38.15
(0.39%)
EUR 38.15
(0.39%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.08 Billion EUR | 109.2% |
| 2022 | 516.44 Million EUR | -11.0% |
| 2021 | 580.3 Million EUR | -4.37% |
| 2020 | 606.8 Million EUR | 9.41% |
| 2019 | 554.61 Million EUR | 82.25% |
| 2018 | 304.32 Million EUR | 19.46% |
| 2017 | 254.74 Million EUR | 56.5% |
| 2016 | 162.77 Million EUR | -7.5% |
| 2015 | 175.97 Million EUR | -3.26% |
| 2014 | 181.91 Million EUR | 18.94% |
| 2013 | 152.94 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.02 Billion EUR | -4.73% |
| 2024 Q2 | 1.07 Billion EUR | 4.77% |
| 2023 Q2 | 1.09 Billion EUR | -3.24% |
| 2023 Q3 | 1.09 Billion EUR | -0.29% |
| 2023 FY | 1.08 Billion EUR | 109.2% |
| 2023 Q1 | 1.13 Billion EUR | 119.99% |
| 2023 Q4 | 1.08 Billion EUR | -1.44% |
| 2022 Q2 | 634.23 Million EUR | 8.86% |
| 2022 Q4 | 516.44 Million EUR | -14.19% |
| 2022 FY | 516.44 Million EUR | -11.0% |
| 2022 Q1 | 582.59 Million EUR | 0.4% |
| 2022 Q3 | 601.88 Million EUR | -5.1% |
| 2021 Q1 | 606.05 Million EUR | -0.12% |
| 2021 FY | 580.3 Million EUR | -4.37% |
| 2021 Q4 | 580.3 Million EUR | -3.56% |
| 2021 Q3 | 601.71 Million EUR | -1.81% |
| 2021 Q2 | 612.8 Million EUR | 1.11% |
| 2020 Q2 | 623.25 Million EUR | 11.76% |
| 2020 Q4 | 606.8 Million EUR | -2.27% |
| 2020 Q1 | 557.65 Million EUR | 0.55% |
| 2020 Q3 | 620.92 Million EUR | -0.37% |
| 2020 FY | 606.8 Million EUR | 9.41% |
| 2019 Q3 | 526.49 Million EUR | 0.86% |
| 2019 FY | 554.61 Million EUR | 82.25% |
| 2019 Q1 | 495 Million EUR | 62.66% |
| 2019 Q2 | 522.02 Million EUR | 5.46% |
| 2019 Q4 | 554.61 Million EUR | 5.34% |
| 2018 Q2 | 321.46 Million EUR | 0.04% |
| 2018 FY | 304.32 Million EUR | 19.46% |
| 2018 Q4 | 304.32 Million EUR | -0.87% |
| 2018 Q3 | 306.98 Million EUR | -4.51% |
| 2018 Q1 | 321.34 Million EUR | 26.14% |
| 2017 Q4 | 254.74 Million EUR | -8.63% |
| 2017 Q3 | 278.81 Million EUR | 0.0% |
| 2017 Q1 | - EUR | -100.0% |
| 2017 FY | 254.74 Million EUR | 56.5% |
| 2016 FY | 162.77 Million EUR | -7.5% |
| 2016 Q4 | 162.77 Million EUR | 0.0% |
| 2015 FY | 175.97 Million EUR | -3.26% |
| 2014 FY | 181.91 Million EUR | 18.94% |
| 2013 FY | 152.94 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| MPH Health Care AG | 13.05 Million EUR | -8176.013% |
| Apontis Pharma AG | 6 Million EUR | -17906.467% |
| Evotec SE | 626.19 Million EUR | -72.531% |
| MERCK Kommanditgesellschaft auf Aktien | 9.94 Billion EUR | 89.132% |
| PharmaSGP Holding SE | 73.97 Million EUR | -1360.438% |
| SynBiotic SE | 3.68 Million EUR | -29256.343% |